Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy
暂无分享,去创建一个
Arjun G. Yodh | Chandra M. Sehgal | Regine Choe | Turgut Durduran | Harry Quon | Susan M. Schultz | Stephen M. Hahn | Susan Schultz | Rosemarie Mick | William M. F. Lee | Xiaoman Xing | Amit Maity | A. Yodh | R. Choe | T. Durduran | C. Sehgal | H. Quon | S. Hahn | A. Maity | C. Koch | S. Evans | R. Mick | William Lee | G. Cerniglia | J. Tsai | Xiaoman Xing | George J. Cerniglia | Nabendu Pore | Jeff H. Tsai | Sydney M. Evans | Cameron J. Koch | N. Pore
[1] M. Dewhirst,et al. Molecular Imaging of Hypoxia , 2011, The Journal of Nuclear Medicine.
[2] C. Bokemeyer,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.
[3] R. Grenman,et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma , 2008, Cancer science.
[4] Weibo Cai,et al. Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.
[5] M. Jacobs,et al. Molecular and Functional MRI of the Tumor Microenvironment , 2008, Journal of Nuclear Medicine.
[6] M. Krause,et al. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials , 2008, Cancer and Metastasis Reviews.
[7] Ralph M Bunte,et al. The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. , 2007, Ultrasound in medicine & biology.
[8] David J. Chen,et al. The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage , 2007, Clinical Cancer Research.
[9] Jens Overgaard,et al. Hypoxic radiosensitization: adored and ignored. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Maity,et al. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. , 2007, Cancer letters.
[11] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Hahn,et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. , 2007, Cancer research.
[13] M. Barcellos-Hoff,et al. Radiation therapy and the microenvironment , 2007, International journal of radiation biology.
[14] Paul Zhang,et al. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. , 2006, The Journal of investigative dermatology.
[15] M. Medina,et al. Anti‐angiogenic drugs: from bench to clinical trials , 2006, Medicinal research reviews.
[16] A. Maity,et al. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. , 2006, Cancer research.
[17] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[18] M. Goldwasser,et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Soff,et al. Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.
[20] David J. Chen,et al. Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.
[21] B. Solomon,et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging , 2005, Molecular Cancer Therapeutics.
[22] M. Krause,et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] S. Varambally,et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). , 2005, Cancer research.
[24] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[25] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[26] Michael J. Emanuele,et al. Treatment-Induced Changes in Tumor Oxygenation Predict Photodynamic Therapy Outcome , 2004, Cancer Research.
[27] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[28] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[29] K. Gelmon,et al. Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction , 2004, Clinical Cancer Research.
[30] C. J. Barnes,et al. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells , 2004, Clinical Cancer Research.
[31] J Martin Brown,et al. Tumor Microenvironment and the Response to Anticancer Therapy , 2002, Cancer biology & therapy.
[32] P. Harari,et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). , 2002, Cancer research.
[33] Lee M Ellis,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Rex Cheung,et al. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. , 2002, Physics in medicine and biology.
[35] G. Fontanini,et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] C. Sehgal,et al. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. , 2001, Radiology.
[37] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] D. O’Rourke,et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. , 2000, Cancer research.
[39] M. Droller. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 2000, The Journal of urology.
[40] E. Conant,et al. Quantitative vascularity of breast masses by Doppler imaging: regional variations and diagnostic implications. , 2000, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[41] P. Harari,et al. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. , 2000, Clinical Cancer Research.
[42] S M Evans,et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.
[43] G. Semenza,et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.
[44] A. Koong,et al. Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.
[45] K. Ang,et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] P. Harari,et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.
[47] G. Tortora,et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[49] C. Koch,et al. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.
[50] J. Baselga,et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. , 1993, Cancer research.
[51] L. Norton,et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. , 1993, Journal of the National Cancer Institute.
[52] J. Mendelsohn,et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. , 1984, Cancer research.
[53] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[54] Kenneth A Krohn,et al. Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.
[55] Amit Maity,et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. , 2003, Cancer research.
[56] C. Koch,et al. Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections. , 2003, Advances in experimental medicine and biology.
[57] Goldman,et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. , 1993, Molecular biology of the cell.
[58] E. Douple,et al. Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin. , 1988, NCI monographs : a publication of the National Cancer Institute.